 |
| |
The World Diabetes Market, 2007-2025: An analysis of Diabetes Drug and Insulin Market gives a detailed analysis on the global diabetes market. This report investigates the top 10 countries: diabetes prevalence, diabetes drug market and insulin market. It also provides a description of the sales and market share of top 10 brands in anti-obesity drug and diabetes drug market globally. This report talks about the prevalence of Impaired Glucose Tolerance (IGT) globally, 20 countries annual health expenditure on diabetes, death due to type 1 and type 2 diabetes globally. Market Overview
In recent years the diabetes drug market and insulin market has shown remarkable growth. This growth is mostly driven by increasing prevalence of diabetes globally and easily availability of insulin in other countries due to its access at an affordable price. The diabetes prevalence is increasing due to changing food habits in the western world leading to obesity.
As the prevalence of obesity and related diseases (diabetes) has increased, so have the sales of drugs to treat them. Top 9 brands of anti-obesity drugs have generated sales of more than US$ 100 Million by November 2007 to October 2008. Whereas, the top eight diabetes drugs generated sales of more than US$ 5 Billion from the period of October 2007 to October 2008.
Although the works are going on to make the oral-pills an alternative for insulin but at present none of the systems have mimics the physiology of insulin secretion. So it is expected that insulin market will keep on growing to reach US$ 15 Billion by 2012. In future Insulin demand will be driven by countries such as US, China, India, Brazil, Russia and Germany.
Countries Analyzed
World Top 10 diabetic populace countries performances on: diabetes prevalence, diabetes drugs market and insulin market (their past, present and future forecast) have been analyzed in this report. The countries covered in this repot are as follows: United States (US), China, India, Brazil, Russia, Germany, Pakistan, Mexico, Egypt and Japan.
Research Highlights
• By 2025 it is expected that India, China and US will be the first, second and third in terms of highest prevalence of diabetes.
• In 2005 use of Non-U100 insulin was very popular in India, Ukraine and Egypt its use was more than 50 percent.
• Anti-obesity drug Meridia and Phentermine Hcl combined corner a market share of more than 65 percent globally from the period of November 2007 to October 2008.
• Anti-diabetic drug Actos (product of Takeda) control the highest market share of 40.5 percent globally from the period of October 2007 to October 2008.
• Diabetes drug Actos sale was highest it was more than twice the sale of its nearest competitor Januvia for the period of October 2007 to October 2008.
• Indian diabetic drug market is expected to be more than Rs. 3,200 Crore by 2010.
• Human insulin market in India has been increased to 30 percent in 2007 compared to 25 percent in 2003.
• In India delivery of insulin using cartridges and pen systems is less than 20 percent but it is growing by 35 percent annually.
• China insulin and analogue market grow by 55.8 percent in the year 2007 compared to 2006.
• Russia insulin market is expected to cross the mark of US$ 600 Million by 2010.
• In 2004 the Mexico insulin market was just 1 percent of its total pharmaceutical market.
Key Players
Novo Nordisk A/S, Sanofi-Aventis, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Servier, Bayer AG, Merck & Co., Eli Lilly and Company, Amylin Pharmaceuticals, Inc., Merck KGaA
Data Sources
The information has been collected from various printable and non-pintable sources like Magazines, Newspapers, Trade Journals, White papers, Online paid databases, News websites Government Agencies and Trade associations.
The World Diabetes Market, 2007-2025: An Analysis of Diabetes Drug and Insulin Market: http://www.companiesandmarkets.com/r.ashx?id=59Wlm1F5t167914
|
—
